Parney et al. found that CD86/granulocyte-macrophage colony-stimulating factor-transduced glioma-derived cells combined with wild type produced increased cytotoxicity of peripheral blood mononuclear cells, which may help determine an optimal glioma immunogene therapy strategy [18]. The gene discussed is CSF2; the disease is central nervous system cancer.